Últimas noticias sobre Smart Sand (NASDAQ:SND) Bolsa

Smart Sand

Smart Sand Inc is a fully integrated frac sand supply and services company that offers complete mine-to-well site proppant supply and logistics solutions. It produces Northern White frac sand, which is a premium proppant used to enhance hydrocarbon recovery rates in the hydraulic fracturing of oil and natural gas wells. Its product portfolio includes Smart System, which includes SmartBelt, SmartDepot Silo and SmartPath Loader. The company caters its products and services to oil and natural gas exploration and production companies and oilfield service companies. The majority of its revenue comes from Sand Sales, followed by logistics.

Smart Sand Inc

Sonida Senior Living Inc

RedHawk Holdings Corp

SANDFIRE RES NL UNSP/ADR by Sandfire Resources NL

Sandfire Resources Ltd

SNDL Inc

Schneider National Inc

SCANDINAVIAN TOB GRP ORD by Scandinavian Tob Group AS

Scandinavian Tobacco Group AS

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals Inc

SUNRIDGE INTL INC by Sunridge International, Inc.

Sunridge International Inc

WIIM

BSFC

Blue Star Foods shares are trading higher after the company announced it signed a vendor agreement with Lowtide.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Goldman Sachs boosted the price target for Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) from $36 to $41. Goldman Sachs analyst Andrea Tan maintained a Neutral rating. Tarsus Pharmaceuticals shares closed at $46.65 on Thursday. <a href="https://www.benzinga.com/quote/TARS/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank boosted the price target for The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) from $115 to $131. Deutsche Bank analyst Bryan Kraft maintained a Buy rating. Disney shares closed at $109.12 on Wednesday. <a href="https://www.benzinga.com/quote/DIS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham raised Agilysys, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGYS#NASDAQ">AGYS</a>) price target from $125 to $145. Needham analyst Mayank Tandon maintained a Buy rating. Agilysys shares settled at $120.84 on Wednesday. <a href="https://www.benzinga.com/quote/AGYS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham cut Applied Materials, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>) price target from $240 to $225. Needham analyst Charles Shi maintained a Buy rating. Applied Materials shares closed at $186.00 on Thursday. <a href="https://www.benzinga.com/quote/AMAT/analyst-ratings">See how other analysts view this stock.</a></li>
<li></li>
<li>Piper Sandler boosted Mastercard Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) price target from $565 to $575. Piper Sandler analyst Arvind Ramnani maintained an Overweight rating. Mastercard shares closed at $520.40 on Thursday.  <a href="https://www.benzinga.com/quote/MA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Benchmark boosted Tower Semiconductor Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSEM#NASDAQ">TSEM</a>) price target from $55 to $60. Benchmark analyst Cody Acree maintained a Buy rating. Tower Semiconductor shares closed at $46.30 on Thursday. See how other analysts view this stock.</li>
<li>Morgan Stanley cut the price target for SolarEdge Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEDG#NASDAQ">SEDG</a>) from $23 to $9. Morgan Stanley analyst Andrew Percoco downgraded the stock from Equal-Weight to Underweight. SolarEdge shares settled at $12.83 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird boosted Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) price target from $294 to $300. Baird analyst Brian Skorney maintained an Outperform rating. Biogen shares closed at $164.89 on Thursday. <a href="https://www.benzinga.com/quote/BIIB/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Baird raised the price target for Palo Alto Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) from $385 to $425. Baird analyst Shrenik Kothari maintained an Outperform rating. Palo Alto shares closed at $394.39 on Thursday. <a href="https://www.benzinga.com/quote/PANW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>HC Wainwright &amp; Co. cut Genelux Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNLX#NASDAQ">GNLX</a>) price target from $32 to $30. HC Wainwright &amp; Co. analyst Emily Bodnar maintained a Buy rating. Genelux shares closed at $2.94 on Thursday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying DIS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="538" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png" alt="" class="wp-image-650089" style="width:581px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-1024x538.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-300x158.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170-768x404.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/15073249/image-170.png 1256w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/42000528/dow-dips-over-200-points-following-economic-reports-tesla-tumbles-on-potential-removal-of-ev-tax-credit-fear-index-remains-in-greed-zone">Dow Dips Over 200 Points Following Economic Reports, Tesla Tumbles On Potential Removal Of EV Tax Credit: Fear Index Remains In &#8216;Greed&#8217; Zone</a></li>
</ul>

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AGYS

AMAT

BIIB

GNLX

PANW

SEDG

TARS

TSEM

Disney To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Friday

Roth MKM analyst Darren Aftahi initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Buy rating and announces Price Target of $25.5.

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Roth MKM Initiates Coverage On Core Scientific with Buy Rating, Announces Price Target of $25.5

Citigourp Global Markets 2% Protected Notes Linked To The Djia

Shares of US-listed Chinese e-commerce companies are trading higher amid possible sympathy with Alibaba Group Holding after the company reported Q2 financial results.

Blue Star Foods Inks Vendor Agreement With Lowtide, Under Wicked Tuna Seafood & Toby Keith's Premium Brands

Wells Fargo analyst Whit Mayo maintains Bank of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>) with a Overweight and raises the price target from $52 to $56.

Wells Fargo Maintains Overweight on Bank of America, Raises Price Target to $56

Truist Securities analyst Ki Bin Kim maintains Brixmor Property Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRX#NYSE">BRX</a>) with a Buy and raises the price target from $28 to $31.

Truist Securities Maintains Buy on Brixmor Property Group, Raises Price Target to $31

Wedbush analyst Nick Setyan reiterates Dine Brands Global (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIN#NYSE">DIN</a>) with a Outperform and maintains $47 price target.

Reiteration

Wedbush Reiterates Outperform on Dine Brands Global, Maintains $47 Price Target

Piper Sandler analyst Edward Tenthoff maintains Omega Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMGA#NASDAQ">OMGA</a>) with a Overweight and lowers the price target from $9 to $4.

OMGA

Piper Sandler Maintains Overweight on Omega Therapeutics, Lowers Price Target to $4

BABA

Alibaba Group Holding shares are trading higher after the company reported better-than-expected Q2 sales results.

Piper Sandler analyst Kashy Harrison upgrades Bloom Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) from Neutral to Overweight and raises the price target from $10 to $20.

Upgrades

Piper Sandler Upgrades Bloom Energy to Overweight, Raises Price Target to $20

Applied Materials shares are trading lower following Q1 financial results. Also, multiple firms lowered their respective price targets on the stock.

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Precigen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGEN#NASDAQ">PGEN</a>) with a Buy and maintains $4 price target.

PGEN

HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $4 Price Target

The World Health Organization (WHO) on Friday described vaccines as &#8220;absolutely critical&#8221; to global health, adding that many people alive today would not have survived childhood without them. This comes at after Donald Trump&#8216;s announcement of Robert F. Kennedy Jr. as Health Secretary.
What Happened: As per <a href="https://pro.benzinga.com">Benzinga Pro</a> on Friday, health stocks declined further during pre-market hours. Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) saw a 0.58% drop after closing 2.62% lower at $26.02. Moderna Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) was down by 1.56% while AstraZeneca plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) fell by 1.41%, and Novavax Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) decreased by 1.39%, having already dropped 7.02% to $7.22.
While the spokesperson for WHO did not comment on Kennedy Jr&#8217;s appointment directly, she mentioned that the U.S. is an important United Nations member and hoped the &#8220;fantastic work&#8221;&nbsp; would continue, <a href="https://www.bbc.com/news/live/c0lp93494g9t?post=asset%3Afdf8e84f-8eb1-45b0-9e05-4ad5adad709b#post">as</a> per BBC news.
Trump&#8217;s decision to appoint Kennedy, known for his vaccine skepticism and conspiracy theories has sparked significant attention. The move aligns with Kennedy&#8217;s recent endorsement of Trump after ending his presidential bid.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Thank you <a href="https://twitter.com/realDonaldTrump?ref_src=twsrc%5Etfw">@realDonaldTrump</a> for your leadership and courage. I&#39;m committed to advancing your vision to Make America Healthy Again. We have a generational opportunity to bring together the greatest minds in science, medicine, industry, and government to put an end to the chronic…
&mdash; Robert F. Kennedy Jr (@RobertKennedyJr) <a href="https://twitter.com/RobertKennedyJr/status/1857198805919138235?ref_src=twsrc%5Etfw">November 14, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also: <a href="https://www.benzinga.com/general/biotech/24/11/41947492/syros-pharmaceuticals-stock-sinks-as-pivotal-blood-cancer-trial-flunks-triggers-loan-default?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Syros Pharmaceuticals Stock Sinks As Pivotal Blood Cancer Trial Flunks, Triggers Loan Default</a>
Why It Matters: The appointment of Kennedy, a prominent critic of vaccines, as Health Secretary could signal a shift in national health policies. Trump&#8217;s choice has <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">elicited mixed reactions</a>, particularly among public health experts. Kennedy&#8217;s stance on vaccines may influence future health regulations and policies.
Kennedy&#8217;s views on vaccines <a href="https://www.benzinga.com/government/regulations/24/11/41993115/trump-taps-rfk-jr-for-health-secretary-role-sends-5-vaccine-stocks-lower">and health agencies diverge sharply</a> from mainstream medical consensus. He has consistently propagated debunked claims, including the false assertion that vaccines cause autism—a theory discredited by extensive scientific research. His nomination for HHS secretary comes amid declining vaccination rates, which have contributed to public health challenges such as 13 measles outbreaks reported in the U.S. this year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41915173/abbvies-schizophrenia-failure-disappoints-but-analysts-show-confidence-in-immunology-portfolio?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">AbbVie&#8217;s Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio</a></li>
</ul>
Image via Shutterstock

Biotech

Health Care

General

MRNA

NVAX

WHO Calls Vaccines 'Absolutely Critical' As Trump's Appointment Of RFK Jr Pulls Pzifer, Moderna Stocks Downhill

Morgan Stanley analyst Simeon Gutman maintains Sally Beauty Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBH#NYSE">SBH</a>) with a Underweight and raises the price target from $8 to $12.

Morgan Stanley Maintains Underweight on Sally Beauty Holdings, Raises Price Target to $12

ValueAct Holdings, L.P. reported holdings worth $3.9 billion in the September quarter after it disclosed major changes in its 13F filing for the third quarter of current fiscal. 
What Happened: One of the major changes in its holdings during Q3 was the addition of 211,500 shares of Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) for $121.07 million, representing 3.08% of its total portfolio.
ValueAct Holdings is a hedge fund popularly known for its activist strategies, run by chief executive officer, Mason Morfit. An activist hedge fund usually follows an event-driven strategy and acquires sufficient equity to influence a company's policies, to increase company value. ValueAct has a long history of investing in technology companies and is generally considered to be more constructivist and collaborative than other activist funds.
ValueAct did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
In 2022, Brad Gerstner&#8216;s Altimeter Capital targeted Meta, urging the company to reduce its workforce. Gerstner articulated his concerns in <a href="https://www.benzinga.com/news/22/10/29380959/meta-investor-proposes-curb-on-employees-strength-metaverse-spending">a letter titled &#8220;Time to Get Fit.</a>
ValueAct fund's specific intentions remain unclear, but CEO Morfit is reportedly supportive of Meta CEO Mark Zuckerberg&#8217;s strategic focus on advancing artificial intelligence initiatives, <a href="https://www.cnbc.com/2024/11/12/activist-valueact-has-1-billion-stake-in-meta-sources-say.html">according</a> to CNBC.
Why It Matters: According to its Q3 <a href="https://13f.info/13f/000141881224000021/compare/000141881224000017">13F filing</a>, ValueAct has acquired a passive stake in the parent company of Facebook, Instagram and WhatsApp, namely, Meta. It is one of the largest companies to be targeted by an activist investor, with a market cap of nearly $1.5 trillion. The hedge fund also increased its investment in <a href="https://www.benzinga.com/m-a/24/01/36471982/disney-partners-with-valueact-capital-for-strategic-counsel-in-anticipation-of-2024-shareholder-meet">The Walt Disney Co</a> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) by adding 1.33 million shares taking its total value to $718.04 million in ValueAct&#8217;s portfolio.
Also Read: <a href="https://www.benzinga.com/economics/macro-economic-events/24/11/42001972/chinese-retail-sales-pickup-in-october-heres-whats-happening-with-alibaba-jd-and-pinduoduo-shares">Chinese Retail Sales Pickup In October: Here&#8217;s What&#8217;s Happening With Alibaba, JD And Pinduoduo Shares</a>
Other Key Changes To The Portfolio
Apart from adding Meta, ValueAct has made some major changes to its portfolio which consists of ten holdings. The fund has increased its stake in the American video game developer Roblox Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>) by adding 7.83 million shares in Q3. It now represents 8.81% of ValueAct&#8217;s portfolio, having a total value of $448.62 million.
Live Nation Entertainment Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>), Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) and Liberty Media Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LLYVK#NASDAQ">LLYVK</a>) are other new holdings that ValueAct has added to its portfolio.
The hedge fund also reduced 806.96 thousand shares in Expedia Group Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>) and completely exited Spotify Technology SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>), Finserv Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), KKR &amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>), New York Times Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NYT#NYSE">NYT</a>) and Flutter Entertainment PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLUT#NYSE">FLUT</a>).
Read next: &nbsp;<a href="https://www.benzinga.com/general/market-summary/24/11/41968003/gold-drops-to-a-two-month-low-as-investors-turn-to-bitcoin-after-trumps-victory-but-this-economist-remains-confident-that-gold-will-surge" target="_blank" rel="noreferrer noopener">Gold Drops To A Two-Month Low As Investors Turn To Bitcoin After Trump's Victory, But This Economist Remains Confident That ‘Gold Will Surge'</a>
Image via Wikimedia Commons

Equities

Tech

EXPE

FLUT

LLYVK

RBLX

SPOT

Activist Hedge Fund ValueAct Boosts Meta Stake With $121M Bet, But CEO Morfit Supports Mark Zuckerberg's AI Vision: Here's What Investors Should Know

Morgan Stanley analyst Chris Quintero maintains BlackLine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BL#NASDAQ">BL</a>) with a Overweight and raises the price target from $70 to $80.

Morgan Stanley Maintains Overweight on BlackLine, Raises Price Target to $80

Morgan Stanley analyst Elizabeth Porter maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Equal-Weight and lowers the price target from $41 to $26.

ZETA

Morgan Stanley Maintains Equal-Weight on Zeta Global Holdings, Lowers Price Target to $26

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates Innate Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPHA#NASDAQ">IPHA</a>) with a Buy and maintains $11.5 price target.

IPHA

HC Wainwright & Co. Reiterates Buy on Innate Pharma, Maintains $11.5 Price Target

Morgan Stanley analyst Michael Phillips maintains Lemonade (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMND#NYSE">LMND</a>) with a Underweight and raises the price target from $15 to $23.

LMND

Morgan Stanley Maintains Underweight on Lemonade, Raises Price Target to $23

Smart Sand, Inc. (SND) Q2 2024 Earnings Call Transcript

Warning: SND is at high risk of performing badly

The latest update is out from Smart Sand ( ($SND) ). Smart Sand, Inc. has secured a new five-year senior secured asset-based credit facility of up ...

Smart Sand Secures New Credit Facility, Ends Previous Agreement

Smart Sand declares $0.10 dividend

Smart Sand ( ($SND) ) has issued an update. Smart Sand, Inc. has announced a special dividend of $0.10 per share and initiated an $10 million share...

Smart Sand Enhances Shareholder Returns with Dividend and Buyback

Smart Sand GAAP EPS of $0.00 misses by $0.01, revenue of $63.16M misses by $3.64M

Reports Q3 revenue $63.2M vs. $73.8M last year. Reports Q3 total tons sold of approximately 1.2M. "We are pleased to report that our continued focu...

Comments

Smart Sand

Noticias

Últimas noticias sobre Smart Sand (NASDAQ:SND) Bolsa

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL